nach oben

Erschienen in:

01.10.2017 | Diabetestherapie | Clinical Practice: Clinical Vignettes

Rhabdomyolysis and AKI with Atorvastatin and Sitagliptin Use in the Setting of Low 25-Hydroxyvitamin D Levels

verfasst von: Rupinder Singh Buttar, MD, Jasveen Batra, MD, Jacqueline Kreimerman, BA, Melissa Aleta, MD, Michal L. Melamed, MD, MHS

Erschienen in: Journal of General Internal Medicine | Ausgabe 10/2017

Einloggen, um Zugang zu erhalten

Abstract

We report a case of an 86-year-old woman admitted to the hospital with rhabdomyolysis and acute kidney injury 3 weeks after starting sitagliptin while on long-term atorvastatin therapy. She also had low levels of 25-hydroxyvitamin D and mild chronic kidney disease, which may have contributed to the development of rhabdomyolysis. A review of the literature reveals four previous reports of this drug interaction in elderly patients, some with underlying kidney disease.

Bhome R, Penn H. Rhabdomyolysis precipitated by a sitagliptin-atorvastatin drug interaction. Diabet Med. 2012;29(5):693–694.CrossRefPubMed

Kao DP, Kohrt HE, Kugler J. Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use. Diabet Med. 2008;25(10):1229–30.CrossRefPubMedPubMedCentral

DiGregorio RV, Pasikhova Y. Rhabdomyolysis caused by a potential sitagliptin-lovastatin interaction. Pharmacotherapy. 2009;29(3):352–6.CrossRefPubMed

Campos-Davila E, Puerto-Alonso J, Perez-Vazquez G, Ramos-Baez J, Marquez-Fernandez E, Guerra-Estevez D. PS-006 Rhabdomyolysis possiblz provoked by a sitagliptin-atorvastatin interaction. Eur J Hosp Pharm: Sci Pract. 2014;21(Suppl 1):A145–6.

Arechavaleta R, Seck T, Chen Y, et al. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2011;13(2):160–8.CrossRefPubMed

Plosker GL. Sitagliptin: a review of its use in patients with type 2 diabetes mellitus. Drugs. 2014;74(2):223–42.CrossRefPubMed

Ovesjo ML, Skilving I, Bergman P, Rane A, Ekstrom L, Bjorkhem-Bergman L. Low vitamin D levels and genetic polymorphism in the vitamin D receptor are associated with increased risk of statin-induced myopathy. Basic Clin Pharmacol Toxicol. 2016;118(3):214–8.CrossRefPubMed

Khayznikov M, Hemachrandra K, Pandit R, Kumar A, Wang P, Glueck CJ. Statin intolerance because of myalgia, myositis, myopathy, or myonecrosis can in most cases be safely resolved by vitamin D supplementation. N Am J Med Sci. 2015;7(3):86–93.CrossRefPubMedPubMedCentral

Bergman AJ, Cote J, Yi B, et al. Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care. 2007;30(7):1862–4.CrossRefPubMed

10.

Pharmacology/ToxicologyReviewandEvaluation-NDA21–995.2006; http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021995s000_PharmR.pdf. Accessed 30 May 2017.

11.

Bergman AJ, Cote J, Maes A, et al. Effect of sitagliptin on the pharmacokinetics of simvastatin. J Clin Pharmacol. 2009;49(4):483–8.CrossRefPubMed

12.

Cerra M, Luo WL, Li SX, et al. The effects of simvastatin on the pharmacokinectics of sitagliptin. J Popul Ther Clin Pharmacol. 2012;19(3):e356–60.PubMed

13.

Scheen AJ. Pharmacokinetic evaluation of atorvastatin and sitagliptin in combination for the treatment of type 2 diabetes. Expert Opin Drug Metab Toxicol. 2012;8(6):745–58.CrossRefPubMed

14.

Alagona P, Jr. Pitavastatin: evidence for its place in treatment of hypercholesterolemia. Core Evid. 2010;5:91–105.CrossRefPubMedPubMedCentral

15.

Lee P, Greenfield JR, Campbell LV. Vitamin D insufficiency—a novel mechanism of statin-induced myalgia? Clin Endocrinol. 2009;71(1):154–5.CrossRef

16.

De Boland AR, Boland RL. Non-genomic signal transduction pathway of vitamin D in muscle. Cell Signal. 1994;6(7):717–24.CrossRefPubMed

17.

Ceglia L, Harris SS. Vitamin D and its role in skeletal muscle. Calcif Tissue Int. 2013;92(2):151–162.CrossRefPubMed

18.

Pleasure D, Wyszynski B, Sumner A, et al. Skeletal muscle calcium metabolism and contractile force in vitamin D-deficient chicks. J Clin Investig. 1979;64(5):1157–67.CrossRefPubMedPubMedCentral

19.

Wang Z, Schuetz EG, Xu Y, Thummel KE. Interplay between vitamin D and the drug metabolizing enzyme CYP3A4. J Steroid Biochem Mol Biol. 2013;136:54–8.CrossRefPubMed

20.

Drocourt L, Ourlin JC, Pascussi JM, Maurel P, Vilarem MJ. Expression of CYP3A4, CYP2B6, and CYP2C9 is regulated by the vitamin D receptor pathway in primary human hepatocytes. J Biol Chem. 2002;277(28):25125–32.CrossRefPubMed

21.

Bhattacharyya S, Bhattacharyya K, Maitra A. Possible mechanisms of interaction between statins and vitamin D. QJM: Mon J Assoc Phys. 2012;105(5):487–491.CrossRef

Titel: Rhabdomyolysis and AKI with Atorvastatin and Sitagliptin Use in the Setting of Low 25-Hydroxyvitamin D Levels
verfasst von: Rupinder Singh Buttar, MD
Jasveen Batra, MD
Jacqueline Kreimerman, BA
Melissa Aleta, MD
Michal L. Melamed, MD, MHS
Publikationsdatum: 01.10.2017
Verlag: Springer US
Schlagwörter: Diabetestherapie
Typ-2-Diabetes
Diabetes in der Hausarztpraxis
Akutes Nierenversagen
Intensivmedizin
Erschienen in: Journal of General Internal Medicine / Ausgabe 10/2017
Print ISSN: 0884-8734
Elektronische ISSN: 1525-1497
DOI: https://doi.org/10.1007/s11606-017-4115-x

Praxisempfehlungen der Deutschen Diabetes Gesellschaft

Kurz, prägnant und aktuell: Die Praxisempfehlungen der Deutschen Diabetes Gesellschaft.

Zu den Praxisempfehlungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2017

Opioids and Substance Abuse: Education or Just Regulation?

Assessing the Burden of Treatment

Incidence and Predictors of Repeat Bone Mineral Densitometry: A Longitudinal Cohort Study

Capsule Commentary on Garland et al., Randomized Controlled Trial of Brief Mindfulness Training and Hypnotic Suggestion for Acute Pain Relief in the Hospital Setting

Capsule Commentary on Kalkhoran et al., Patterns of and Reasons for Electronic Cigarette Use in Primary Care Patients

Patterns of and reasons for electronic cigarette use in primary care patients

Praxisempfehlungen der Deutschen Diabetes Gesellschaft